Trial Profile
PBTC-053: A Pediatric Brain Tumor Consortium Phase I/ II and Surgical Study of CX-4945 in Patients With Recurrent SHH Medulloblastoma
Status:
Suspended
Phase of Trial:
Phase I/II
Latest Information Update: 09 Apr 2024
Price :
$35
*
At a glance
- Drugs Silmitasertib (Primary)
- Indications Medulloblastoma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 06 Mar 2024 Status changed from recruiting to suspended due to drug supply issues.
- 25 Jan 2024 Planned primary completion date changed from 7 Sep 2028 to 8 Sep 2028.
- 22 Jan 2024 Planned primary completion date changed from 8 Sep 2028 to 8 Dec 2028.